SMT201400134B - Composizioni coadiuvanti comprendenti un agente diisotonicita' non ionico - Google Patents

Composizioni coadiuvanti comprendenti un agente diisotonicita' non ionico

Info

Publication number
SMT201400134B
SMT201400134B SM201400134T SM201400134T SMT201400134B SM T201400134 B SMT201400134 B SM T201400134B SM 201400134 T SM201400134 T SM 201400134T SM 201400134 T SM201400134 T SM 201400134T SM T201400134 B SMT201400134 B SM T201400134B
Authority
SM
San Marino
Prior art keywords
diisotonicity
ionic
agent
adjuvant compositions
adjuvant
Prior art date
Application number
SM201400134T
Other languages
English (en)
Italian (it)
Inventor
Veronique Henderickx
Dominique Ingrid Lemoine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400134(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SMT201400134B publication Critical patent/SMT201400134B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM201400134T 2009-06-10 2014-09-15 Composizioni coadiuvanti comprendenti un agente diisotonicita' non ionico SMT201400134B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0910046.2A GB0910046D0 (en) 2009-06-10 2009-06-10 Novel compositions
PCT/EP2010/058017 WO2010142685A1 (fr) 2009-06-10 2010-06-08 Compositions adjuvantes contenant un agent d'isotonicité non ionique

Publications (1)

Publication Number Publication Date
SMT201400134B true SMT201400134B (it) 2014-11-10

Family

ID=40937237

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400134T SMT201400134B (it) 2009-06-10 2014-09-15 Composizioni coadiuvanti comprendenti un agente diisotonicita' non ionico

Country Status (31)

Country Link
US (2) US20120087976A1 (fr)
EP (1) EP2440242B1 (fr)
JP (3) JP5647677B2 (fr)
KR (1) KR101473686B1 (fr)
CN (2) CN104367997B (fr)
AU (1) AU2010257538B2 (fr)
BR (1) BRPI1012890B1 (fr)
CA (1) CA2764421C (fr)
CL (1) CL2011003113A1 (fr)
CO (1) CO6440528A2 (fr)
CY (1) CY1115522T1 (fr)
DK (1) DK2440242T3 (fr)
DO (1) DOP2011000346A (fr)
EA (1) EA024074B1 (fr)
ES (1) ES2494442T3 (fr)
GB (1) GB0910046D0 (fr)
HR (1) HRP20140792T1 (fr)
IL (1) IL216231A0 (fr)
MA (1) MA33412B1 (fr)
MX (1) MX2011013162A (fr)
MY (1) MY159819A (fr)
NZ (1) NZ596503A (fr)
PE (1) PE20120319A1 (fr)
PL (1) PL2440242T3 (fr)
PT (1) PT2440242E (fr)
RS (1) RS53550B1 (fr)
SG (1) SG176638A1 (fr)
SI (1) SI2440242T1 (fr)
SM (1) SMT201400134B (fr)
UA (1) UA104888C2 (fr)
WO (1) WO2010142685A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2668775T3 (es) 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
MX355836B (es) 2010-08-20 2018-05-02 Chugai Pharmaceutical Co Ltd Composicion que comprende compuestos tetraciclicos.
DK2651436T3 (da) * 2010-12-14 2016-06-20 Glaxosmithkline Biologicals Sa Mycobakterie antigen sammensætning.
US10668075B2 (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
CA2943190A1 (fr) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Formulation d'adjuvant non toxique comprenant une composition de liposomes contenant un lipide a monophosphoryle (mpla) et une saponine
EP3135671B1 (fr) 2014-04-25 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Nouveau cristal de composé tétracyclique
WO2015163448A1 (fr) 2014-04-25 2015-10-29 中外製薬株式会社 Préparation contenant un composé tétracyclique à haute dose
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含4環性化合物的非晶質體之固體分散體及製劑
JP6741596B2 (ja) 2015-01-16 2020-08-19 中外製薬株式会社 併用医薬
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
EP3551222B1 (fr) * 2016-12-07 2024-08-07 GlaxoSmithKline Biologicals SA Procede de fabrication d'une composition de liposome comprenant une saponine
AU2018258070A1 (en) 2017-04-25 2019-10-24 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2018220553A1 (fr) 2017-05-30 2018-12-06 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un arn encapsulé dans un liposome
WO2019079160A1 (fr) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. Analogues de saponine triterpénique
WO2019106192A1 (fr) * 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Purification de saponine
BR112020010635A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. extração de saponina
CN112384223B (zh) 2018-06-29 2024-08-27 中外制药株式会社 含有难溶性碱性药剂的药物组合物
WO2020050241A1 (fr) 2018-09-04 2020-03-12 中外製薬株式会社 Procédé de production de composé tétracyclique
WO2020109365A1 (fr) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un adjuvant
JP7640473B2 (ja) * 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CA3148928A1 (fr) * 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Procede de preparation d'une composition comprenant un polypeptide de proteine d
EP4021407A1 (fr) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Procédé de fabrication de nanoparticules lipidiques mélangées par jet
AU2024237452A1 (en) * 2023-03-15 2025-10-23 United Immunity, Co., Ltd. Lipid particle
WO2025180443A1 (fr) * 2024-02-29 2025-09-04 Immunadd Inc. Composition d'adjuvant, composition pharmaceutique la comprenant, et méthode de prévention ou de traitement d'une maladie provoquée par une infection virale, une infection bactérienne, une infection protozoaire ou un cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
ATE513042T1 (de) 1998-02-05 2011-07-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
HK1039072A1 (zh) * 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
JP3765232B2 (ja) 2000-11-16 2006-04-12 株式会社ジェイテクト 電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1829887B1 (fr) * 2004-11-29 2011-08-24 Changchun Huapu Biotechnology Co., Ltd. Desoxynucleotides cpg a brin unique a utiliser comme adjuvant
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
KR20090101313A (ko) 2007-01-15 2009-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
MX2009007572A (es) 2007-01-15 2009-10-13 Glaxosmithkline Biolog Sa Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
KR101238795B1 (ko) * 2007-05-24 2013-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
ES2494442T3 (es) 2014-09-15
AU2010257538A1 (en) 2011-12-08
CN104367997A (zh) 2015-02-25
MY159819A (en) 2017-02-15
MX2011013162A (es) 2012-01-30
GB0910046D0 (en) 2009-07-22
NZ596503A (en) 2013-08-30
CL2011003113A1 (es) 2012-08-31
CY1115522T1 (el) 2017-01-04
JP2016193912A (ja) 2016-11-17
AU2010257538B2 (en) 2016-10-20
RS53550B1 (sr) 2015-02-27
CA2764421A1 (fr) 2010-12-16
DOP2011000346A (es) 2012-01-15
JP2012529464A (ja) 2012-11-22
CN102458457B (zh) 2015-05-20
PL2440242T3 (pl) 2014-11-28
KR101473686B1 (ko) 2014-12-18
US20120087976A1 (en) 2012-04-12
EA024074B1 (ru) 2016-08-31
IL216231A0 (en) 2012-01-31
WO2010142685A1 (fr) 2010-12-16
US20180021417A1 (en) 2018-01-25
JP5977789B2 (ja) 2016-08-24
KR20120031497A (ko) 2012-04-03
EP2440242A1 (fr) 2012-04-18
PT2440242E (pt) 2014-08-29
SG176638A1 (en) 2012-01-30
JP6261647B2 (ja) 2018-01-17
MA33412B1 (fr) 2012-07-03
UA104888C2 (uk) 2014-03-25
EP2440242B1 (fr) 2014-06-25
JP5647677B2 (ja) 2015-01-07
CN102458457A (zh) 2012-05-16
CO6440528A2 (es) 2012-05-15
CN104367997B (zh) 2019-01-22
DK2440242T3 (da) 2014-09-01
SI2440242T1 (sl) 2014-09-30
HRP20140792T1 (hr) 2014-10-10
PE20120319A1 (es) 2012-04-16
BRPI1012890B1 (pt) 2022-03-22
BRPI1012890A2 (en) 2018-02-27
CA2764421C (fr) 2016-12-06
EA201190286A1 (ru) 2012-06-29
JP2015042646A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
SG176638A1 (en) Adjuvant compositions comprising a non-ionic isotonicity agent
ZA200904935B (en) Benefit agent delivery compositions
EP2280916A4 (fr) Compositions d'hydrochlorofluoro-oléfines
PL2837383T3 (pl) Środek indukujący odporność
ME02979B (fr) Compositions d'hémoglobine
ZA201300073B (en) Compositions comprising optical benefit agents
BR112012000652A2 (pt) composições contendo partículas de liberação de agente de benefício
IL205915A0 (en) Tapentadol compositions
BRPI0914746A2 (pt) composições fungicidas
EP2655457A4 (fr) Composition d'électroplacage de métaux comprenant un agent d'étalement
EP2332425A4 (fr) Agent d'amélioration d'arôme
EP2163603A4 (fr) Composition d'un agent tensio-actif
BR112012005247A2 (pt) agente antifitoviral
BRPI1008215A2 (pt) "composição azeotrópica"
EP2018182A4 (fr) Compositions immunogenes
EP2463316A4 (fr) Composition d'acrylate
BRPI1011051A2 (pt) "desinfetante para as mãos"
FR2957350B1 (fr) Compositions d'agent d'expansion a base d'hydrochlorofluoroolefine
EP2537907A4 (fr) Composition d'agent antiadhésif
EP2515938A4 (fr) Compositions immunogènes
ZA201103338B (en) Cleansing compositions
ATE534721T1 (de) Reinigungsmittelzusammensetzung
BRPI0817999A2 (pt) Composição oral compreendendo um agente de resfriamento
IL200274A0 (en) Pharmaceutical compositions comprising a calcilytic agent
EP2692715A4 (fr) Composition d'agent gazogène